Canary Health Technologies develops RNA and gene therapies utilizing lipid nanoparticles and RNA interference to target genetic defects in rare neurological disorders and severe obesity. Their approach aims to restore protein function and metabolic health, addressing the unmet medical needs of patients with conditions previously deemed untreatable.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for rare neurological disorders and severe obesity often fail to address the underlying genetic causes, leaving many patients with limited or ineffective options. Existing therapies may also have significant side effects or require frequent dosing, reducing patient compliance and overall effectiveness.
Solution
Canary Health Technologies is developing RNA interference (RNAi) and gene therapies that target the genetic roots of rare neurological disorders and severe obesity. Their approach utilizes lipid nanoparticles (LNPs) and vectorized antibodies to deliver therapeutic genes and vectorized antibodies directly to affected cells and tissues. For obesity, their siRNA therapeutics promote the browning of white fat to increase metabolism and facilitate sustainable weight loss, while preserving lean body mass. For rare neurological diseases, they focus on restoring myelin integrity and neurological function by correcting underlying genetic and proteinopathies. Their LNP-mRNA platform is designed for targeted delivery of mRNA, instructing cells to produce beneficial proteins or correct abnormal protein production.
Target Audience
The primary target audience includes individuals with rare neurological disorders, patients with severe obesity and associated metabolic complications, and children with severe pediatric obesity.
Features
- Dual RNAi gene silencing to simultaneously target CB1r and zfp423 for obesity treatment
- LNP-mRNA therapies for targeted delivery of functional proteins in rare neurological diseases
- Novel vectors capable of delivering therapeutic genes and vectorized antibodies directly to targeted cells and tissues
- Proprietary vectorized antibodies designed to specifically bind and neutralize misfolded proteins
- RNAi therapeutics that modulate gene expression and correct underlying genetic defects
- AI-supported research and accelerated regulatory pathways for efficient drug development
- Thermogenesis activation to boost calorie burning and utilize stored fat for obesity treatment
- Peripheral restriction of therapeutics to minimize potential side effects in the central nervous system